CHMP recommends approval of Privigen® (human normal immunoglobulin) for chronic inflammatory demyelinating polyneuropathy

Source: European Medicines Agency Area: News The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended a variation to the terms of the marketing authorisation for Privigen® (human normal immunoglobulin). The CHMP recommends the adoption of a new indication: the treatment of adults, and children and adolescents (0-18 years) with chronic inflammatory demyelinating polyneuropathy (CIDP).  Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.   Detailed recommendations for the use of this product will be described in the updated Summary of Product Characteristics, which will be available after the variation to the marketing authorisation has been granted by the European Commission.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news